Apr 23 |
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
|
Apr 16 |
Palisade Bio stock rallies nearly 100% on colitis drug analysis
|
Apr 16 |
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
|
Apr 11 |
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
|
Apr 10 |
Palisade Bio stock slides 8% amid colitis drug presentation
|
Apr 10 |
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
|
Apr 3 |
Palisade Bio announces 1-for-15 reverse stock split
|
Apr 3 |
Palisade Bio Announces 1-for-15 Reverse Stock Split
|
Mar 27 |
Palisade Bio GAAP EPS of -$1.80 misses by $0.85, revenue of $0.25M
|
Mar 27 |
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
|